ENZARAD Trial

Trial Title:

Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: a randomised phase III trial

Trial Acronym:

ENZARAD

Protocol Number:

ANZUP 1303

Trial Design:

Open label, randomised, stratified, 2-arm multicentre phase 3 clinical trial

Collaborators:

ICORG, TROG, Dana-Farber Cancer Institute

ANZ Study Chairs:

Scott Williams and Paul Nguyen

ANZ Coordinating Centre:

NHMRC CTC

Trial Coordinator:

Emily Tu

Trial Email:

enzarad@ctc.usyd.edu.au

Patient Population:

The target population is men with localised prostate cancer at high risk for recurrence deemed suitable for external beam radiation therapy

Intervention:

Enzalutamide 160mg daily by mouth combined with LHRHA and external beam radiation therapy

Primary Outcome:

Overall survival (death from any cause)

Secondary Outcomes:

Status:

Closed to recruitment

Sites Recruiting:

Further Information:

Click here